内科

目的探讨培美曲塞、顺铂联合125I粒子植入治疗晚期非小细胞肺癌（NSCLC）患者的临床效果。方法将2018年7月至2019年7月在我院接受治疗的68例晚期NSCLC患者采用随机数字法分为观察组与对照组，每组34例。对照组患者接受培美曲塞、顺铂方案化疗，观察组患者接受培美曲塞、顺铂方案化疗联合125I粒子植入放疗。治疗3个月后，比较两组患者的血清细胞角蛋白19片段（CYFRA 21-1）与神经元特异性烯醇化酶（NSE）水平；比较两组患者的近期临床疗效和生活质量。结果治疗前，两组患者的CYFRA 21-1、NSE水平比较，差异无统计学意义（P＞0.05）；治疗3个月后，两组患者的CYFRA 21-1、NSE水平均明显下降，观察组患者的水平显著低于对照组，差异有统计学意义（P＜0.05）；观察组患者的治疗总有效率（82.35%）明显高于对照组（55.88%），差异有统计学意义（P＜0.05）。治疗前，两组患者的躯体功能、心理功能、社会功能及物质生活评分比较，差异无统计学意义（P＞0.05）；治疗3个月后，两组患者的躯体功能、心理功能、社会功能及物质生活评分均明显增高，观察组患者的评分显著高于对照组，差异有统计学意义（P＜0.05）。结论培美曲塞、顺铂联合125I粒子植入治疗晚期非小细胞肺癌患者的近期疗效良好，能有效改善患者的病情，提高患者的生活质量。

ObjectiveTo explore the clinical effects of pemetrexed, cisplatin combined with 125I particle implantation in treating patients with advanced non-small cell lung cancer (NSCLC). MethodsA total of 68 patients with advanced NSCLC who were treated in our hospital from July 2018 to July 2019 were divided into observation group and control group according to the random number method, with 34 cases in each group. The patients in the control group received pemetrexed and cisplatin chemotherapy, and the patients in the observation group were given pemetrexed, cisplatin chemotherapy combined with 125I particle implantation radiation therapy. After 3 months of treatment, the levels of serum cyto-keratin 19 fragment antigen 21-1 (CYFRA 21-1) and neuron specific enolase (NSE), short-term clinical efficacy and life quality were compared between the two groups of patients. ResultsBefore treatment, there were no statistically significant differences in the levels of CYFRA 21-1 and NSE between the two groups (P＞0.05). After 3 months of treatment, the levels of CYFRA 21-1 and NSE significantly decreased in both groups and the levels in the observation group were significantly lower than those in the control group, with statistically significant differences (P＜0.05). The total effective treatment rate of patients in the observation group (82.35%) was significantly higher than that of the control group (55.88%), with a statistically significant difference (P＜0.05). Before treatment, there were no statistically significant differences in the scores of physical function, psychological function, social function and material life between the two groups (P＞0.05). After 3 months of treatment, the scores of physical function, psychological function, social function and material life increased significantly in both groups, and the scores of patients in the observation group were significantly higher than those of the control group, with statistically significant differences (P＜0.05). ConclusionPemetrexed, cisplatin combined with 125I particle implantation in the treatment of patients with advanced NSCLC has a good short-term efficacy, which can effectively improve the condition and the life quality of patients.